Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) EBT: 2016-2024

Historic EBT for Summit Therapeutics (SMMT) over the last 3 years, with Dec 2024 value amounting to -$65.6 million.

  • Summit Therapeutics' EBT fell 81.23% to -$65.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$183.2 million, marking a year-over-year decrease of 94.97%. This contributed to the annual value of -$234.7 million for FY2024, which is 61.84% up from last year.
  • Per Summit Therapeutics' latest filing, its EBT stood at -$65.6 million for Q4 2024, which was down 7.88% from -$60.8 million recorded in Q3 2024.
  • Summit Therapeutics' EBT's 5-year high stood at -$7.4 million during Q1 2020, with a 5-year trough of -$65.6 million in Q4 2024.
  • Its 3-year average for EBT is -$36.7 million, with a median of -$28.4 million in 2023.
  • Data for Summit Therapeutics' EBT shows a maximum YoY slumped of 196.86% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Summit Therapeutics' EBT stood at -$7.4 million in 2020, then reached -$20.3 million in 2022, then slumped by 78.38% to -$36.2 million in 2023, then slumped by 81.23% to -$65.6 million in 2024.
  • Its last three reported values are -$65.6 million in Q4 2024, -$60.8 million for Q3 2024, and -$36.2 million during Q4 2023.